STING1 and neoplasm: PARP inhibition has been reported to induce DNA damage and cGAS-STING–dependent interferon signaling in BRCA-mutant breast and ovarian cancers28, 29, therefore we hypothesize that D + O + C treatment may require immunoreactive tumor milieu at baseline for its efficacy and less relying on a metabolically favorable baseline state, requiring further validation.